ROCO
6572
Market cap24mUSD
Oct 08, Last price
7.57TWD
1D
6.77%
1Q
0.26%
Jan 2017
-70.66%
IPO
-81.14%
Name
PlexBio Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
PlexBio Co., Ltd. is dedicated to the creation and production of in vitro diagnostic (IVD) solutions for both molecular biology and immunology purposes. Their comprehensive product range features services for optimizing diagnostic workflows, as well as automated kits for sample preparation and extraction. A key innovation is their IntelliPlex platform, which leverages pCode technology to enable advanced, "sample-to-answer" multiplexing assays. The company also supplies specialized oncology panels designed for detecting lung cancer, gene mutations, and chromosomal rearrangements. Additionally, PlexBio offers a variety of infectious disease tests, including IntelliPlex kits for SARS-CoV-2 detection, influenza, and SARS-CoV-2 variant analysis, complemented by essential reagents such as pCode coupling buffer sets. Founded in 2009, PlexBio Co., Ltd. operates from its headquarters in Taipei, Taiwan.
Key people
Libi Ye
Chief Financial Officer · since 2017
Dean Tsao
Chairman of the Board, Chief Operating Officer, General Manager · since 2020
Director · since 2019
Yasuhiro Ohashi
Director · since 2019
Mingde Chen
Independent Director · since 2025
Yijun Lai
Director · since 2025
Independent Director · since 2016
Sonny Wang
Independent Director · since 2021
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||